Skip to main content

PBM · Psyence Biomedical Ltd. · Financials

Track PBM — free
$4.98 -0.10 (-1.97%)
Market Cap
$21.21M
Shares
3.81M
Volume · Oct 6 39.41K Avg daily vol (3M) 92.79K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Net Income
-$6.94M -785.6%
FY2026 Net Income FY2023–FY2026
Diluted EPS
-$12.56 -138.3%
FY2026 Diluted EPS FY2023–FY2026
Operating Cash Flow
-$8.14M -118.1%
FY2026 Operating Cash Flow FY2023–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 FY2025 FY2024 FY2023
$1.47M $342.17K $954.59K $1.61M
$218.49K $483.53K $80.6K $7029
$892.26K $1.21M $557.9K $366.44K
$5266 $4268 $240 —
— — $52.94K —
-$6.23M -$3.66M -$2.75M -$3.23M
-$6.94M $1.01M -$51.16M -$3.21M
USD/shares -$12.56 $32.76 -$29,214.06 -$15,392.97
USD/shares -$12.56 $32.76 -$29,214.06 -$15,392.97
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Short-term borrowings 2026-03-31 USD 251,110 20-F filed 2026-06-22
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1985062 CUSIP 74449F407 Visit website Investor relations